CD73 Serves as a Prognostic Biomarker and Therapeutic Target in Combination With Lorlatinib for ALK-Positive NSCLC

oleclumab (MEDI9447) - AstraZeneca

ciforadenant (CPI-444) - Corvus Pharma

Lorbrena (lorlatinib) - Pfizer

Z-R. Ren; J-j. Gu; D-X. Cai; Z-Y. Zhou; C. Lu; Z-H. Chen; Y. Deng; Y-J. Lin; C-R. Xu; Q. Zhou

Jul 31, 2026